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Previewswith a nucleating factor(s) to promote
actin motility. It is known that profilin and
formins interact in such a manner. Thus,
profilin-actin complexes may bind to the
formin-homology (FH) domain of formin,
which can in turn nucleate actin polymer-
ization and bind to barbed ends proces-
sively as the filaments grow. Formin-profi-
lin complexes can thereby cooperatively
enhance filament elongation at barbed
ends. However, Serio et al. (2010) tested
six Drosophila formins, but none was
required for Rickettsia motility, though
it remains possible that these proteins
play a redundant role. Alternatively, in
a manner analogous to ActA in Listeria,
the bacteria may itself encode a formin-
like protein. In this regard, R. rickettsii
Sca2 is required for motility and virulence
(Kleba et al., 2010); it will be interesting to
see whether the protein encoded by this
gene contains an FH-like domain that
interacts with profilin.336 Cell Host & Microbe 7, May 20, 2010 ª20UsingRickettsia, Serio et al. (2010) have
revealed the function of a set of cytoskel-
etal proteins whose role in actin dynamics
have been suspected but never so clearly
defined. With Rickettsia, it will be inter-
esting to see whether the RickA-Arp2/3
or Sca2-profilin complexes catalyze dis-
tinct actin-dependent processes during
infection. Indeed, it may turn out that
many pathogens use both actin polymer-
ization systems. Such explorations may,
in turn, elucidate novel regulatory sig-
naling mechanisms as well as an under-
standing of how normal cells control actin
dynamics.
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Viral infection leads to the rapid production of type I interferons within infected tissues. In this issue of Cell
Host &Microbe, Hermesh et al. (2010) demonstrate that interferons produced following respiratory viral infec-
tion program leukocytes in the bone marrow to resist infection before trafficking to the lung.Immune responses to viral infection of the
respiratory tract are triggered by the
innate recognition of pathogen-associ-
ated molecular patterns. One of the
earliest antiviral responses is the
synthesis of type I interferons (IFNs),
which can signal back to the infected
cell, as well as to surrounding cells,
through the ubiquitously expressed
IFNa/b receptor. Signaling through the
IFNa/b receptor initiates a positive feed-
back loop, resulting in enhanced IFN
production, the expression of genes that
inhibit viral replication, and the amplifica-
tion of the antiviral response (Moltedoet al., 2009). Concomitantly, a robust
inflammatory response, including the
production of cytokines and chemokines,
serves to recruit leukocytes to the lung.
Hermesh and colleagues now show that
type I IFNs produced in the lung can
interact directly with leukocytes residing
in the bone marrow, activating antiviral
transcription programs that protect these
cells from infection with a wide range of
viruses (Hermesh et al., 2010). Taken in
broader context, these findings demon-
strate that peripheral infections can
‘‘communicate’’ with leukocytes in the
bone marrow, priming these cells to resistinfection prior to their arrival in infected
tissues, thus promoting their survival and
assuring their ability to carry out antiviral
functions (Figure 1).
The ability of type I IFNs to induce anti-
viral gene expression and inhibit viral
replication within infected tissues has
been well described (Katze et al., 2002).
However, previous models for the effect
of type I INFs on migrating leukocytes
during peripheral infections assumed
that IFNa/b receptor signaling, and
expression of IFN-inducible genes,
occurred once leukocytes migrated to in-
fected tissues. Hermesh et al. (2010) used
Figure 1. Type I IFNs Produced in the Lung following Respiratory Virus Infection Program
Bone Marrow-Resident Leukocytes to Resist Viral Infection
Following respiratory virus infections, type I IFNs travel from the lung to the bone marrow, where they acti-
vate resident leukocytes. These leukocytes initiate an antiviral transcription program, rendering the cells
resistant to viral infection prior to their migration from the bone marrow to the infected lung. Once in the
lung, protected leukocytes promote viral clearance through the production of proinflammatory cytokines
and chemokines.
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Previewsmurine models of influenza and parain-
fluenza virus infection to conclusively
show that leukocytes in the bone marrow
expressed IFN-inducible genes despite
the fact that neither influenza nor parain-
fluenza viruses were detected in the blood
or bone marrow. This is consistent with
previous studies in both mice and hu-
mans, wherein type I IFNs were detected
in the serum following influenza infection
even though viral replication is limited to
the lung (Hayden et al., 1998; Horisberger
and De Staritzky, 1989). Therefore, the
observed phenotype could only be due
to the transport of cytokines from the
lung, rather than from a low-level
systemic infection. Importantly, using
mixed bone marrow chimeras in which
some leukocytes lacked expression of
the IFNa/b receptor, Hermesh and
colleagues show that type I IFNs, and
not other inflammatory cytokines, are
responsible for initiating the antiviral tran-
scription program in bone marrow-resi-
dent leukocytes.
Although a role for bone marrow-
derived leukocytes in immunity to respira-
tory viruses has been previously estab-
lished (Lin et al., 2008), the importance
of IFNa/b receptor signaling in these cells
had not been investigated. Hermesh et al.
(2010) find that type I IFNs produced
following influenza and parainfluenzaviruses induce the resistance of bone
marrow leukocytes to infection by both
RNA and DNA viruses, demonstrating
that this mechanism can provide broad
protection from many different patho-
gens. Most importantly, resistance to
infection was essential for the antiviral
functions of bone marrow-derived leuko-
cytes once they migrated to the lung.
They show that wild-type leukocytes re-
cruited to the lung exhibit lower levels of
viral RNA compared to IFNa/b receptor-
deficient leukocytes. However, despite
lower levels of viral RNA, wild-type leuko-
cytes show significantly higher transcrip-
tion of proinflammatory cytokines and
chemokines. This enhanced resistance
to infection and cytokine production had
a significant impact on the course of
infection, as chimeric mice in which the
entire hematopoietic compartment had
been replaced with cells lacking the
IFNa/b receptor showed defective viral
clearance.
Taken together, the data presented by
Hermesh and colleagues show that leuko-
cytes can be primed by type I IFNs in the
bone marrow following respiratory virus
infection, and these primed cells can infil-
trate the lung to produce cytokines while
being protected with viral infection. These
findings demonstrate a previously unrec-
ognized link between peripheral immuneCell Host & Microbsurveillance and the primary site of hema-
topoiesis, whereby type I IFNs serve as
‘‘messengers’’ that alert the sterile bone
marrow to a localized infection. The
communication between the periphery
and the bone marrow during infection
suggests several avenues for further
investigation. First, although type I IFNs
are detected in the blood during respira-
tory virus infection, it is not clear whether
this is the sole route for delivering IFNs
to the bone marrow. It is possible that
travel through the lymphatic system, or
low levels of localized production, may
be important for the type I IFN-mediated
instruction of bone marrow leukocytes.
Second, the ability of localized peripheral
infections to rapidly signal the bone
marrow via type I IFNs may also influence
recall responses because memory B and
T cells are preferentially maintained in
the bone marrow (Kohlmeier and Wood-
land, 2009). Finally, the data raise the
possibility that immunosupressed individ-
uals, who are often prone to viral infec-
tions, may benefit from low-dose type I
IFN therapy. Overall, these findings show
that appropriate instruction of bone
marrow leukocytes is required for optimal
control of respiratory viral infections and
suggest a fundamental mechanism by
which the localized infections can mobi-
lize a systemic immune response.ACKNOWLEDGMENTS
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